AzTrials
AzTrials

Vaginal Vault ProlapseLite-YNCT03681223

Restorelle® Y Mesh vs. Vertessa® Lite Y Mesh for Laparoscopic and Robotic-assisted Laparoscopic Sacrocolpopexy

A study testing Vertessa® Lite Y mesh, Restorelle® Y mesh and Laparoscopic sacrocolpopexy in people with Vaginal Vault Prolapse, run by The Cleveland Clinic at 1 site in United States.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

This is a randomized clinical trial to compare outcomes between the Restorelle® Y mesh and Vertessa® lite Y mesh for the treatment of vaginal vault prolapse. Hypothesis: Vertessa® lite Y mesh is not inferior to Restorelle® Y mesh for the treatment of vaginal vault prolapse Read more about this study

Who is it for?
Ages 18 years and older, women only
Conditions the study is for
Vaginal Vault Prolapse
What is being tested?
Vertessa® Lite Y mesh, Restorelle® Y mesh and Laparoscopic sacrocolpopexy
Could I receive a placebo?
No, everyone receives an active treatment
How many people
106 participants
Where
1 siteUnited States
Study dates
18 Sep 2018to 19 Dec 2023
Phase
Interventional
Are there results?
Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • Women only
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Age ≥ 18, who are to undergo laparoscopic or robotic laparoscopic sacrocolpopexy for pelvic organ prolapse
  • Other concomitant laparoscopic or prolapse and anti-incontinence procedures (e.g., laparoscopic supracervical hysterectomy, cystocele repair, rectocele repair or mid-urethral sling procedures) will be performed at the primary surgeon's discretion.

Who cannot join

  • Inability to comprehend written and/or spoken English
  • Inability to provide informed consent
  • Medical illness precluding laparoscopy
  • Need for concomitant surgeries not related to pelvic organ prolapse or incontinence
  • Sacrocolpoperineopexy
  • Need for dual flat mesh for sacrocolpopexy procedure (determined by surgeon)

Trial locations and contacts

1 site in 1 country.

United States1 site
  • Cleveland Clinic

    Cleveland, Ohio, 44195

Other trials in United States

About this study

Official title: A Prospective Randomized Trial Comparing Restorelle® Y Mesh vs. Vertessa® Lite Y Mesh for Laparoscopic and Robotic-assisted Laparoscopic Sacrocolpopexy

This is a randomized clinical trial to compare outcomes between the Restorelle® Y mesh and Vertessa® lite Y mesh for the treatment of vaginal vault prolapse.

Hypothesis: Vertessa® lite Y mesh is not inferior to Restorelle® Y mesh for the treatment of vaginal vault prolapse

Read the detailed description

This is a randomized single-blind, non-inferiorty trial. Abdominal sacrocolpopexy is considered the gold standard for vault prolapse, and has demonstrated superior anatomic outcomes compared to transvaginal suspension procedures. Sacrocolpopexy involves suspension of the vagina to the anterior longitudinal ligament of the sacrum at the level of S1 using a bridging graft which can be made of biologic or synthetic materials. The graft is sutured to the anterior as well as the posterior vagina and then attached to the anterior longitudinal ligament of the sacrum. ). Both the Restorelle® Smartmesh (Coloplast, Inc., Minneapolis, MN, USA) and the Vertessa® lite mesh (Caldera Medical. Inc., Agoura Hills, CA, USA) are ultra-light macroporous polypropylene mesh grafts that are intended for pelvic floor reconstruction, both types of grafts are used to perform sacrocolpopexy. Currently no prospective data exists on the Vertessa® lite mesh for sacrocolpopexy. It is used by many surgeons, but there are no data showing that it is as efficacious in treating prolapse and avoiding mesh erosion in those patients undergoing sacrocolpopexy. Therefore, the primary objective of the proposed study is to compare outcomes between the Restorelle® Y mesh and Vertessa® lite Y mesh at the time of laparoscopic and robotic-assisted laparoscopic sacrocolpopexy.

Study subjects will be recruited from patients that present to the Center for Urogynecology \& Pelvic Reconstructive Surgery in the Department of Obstetrics and Gynecology at the Cleveland Clinic Main campus, Hillcrest Hospital and Fairview Hospital, and their surgeries will be performed at either one of these sites. All subjects will be predetermined by their surgeon to undergo either a laparoscopic or robotic assisted laparoscopic sacrocolpopexy depending upon their clinical evaluation. The subjects will then we randomized to either Restorelle® or Vertessa® Y sacrocolpopexy according to a computer-generated randomization schedule with random block sizes with the use of the SAS statistical software package (SAS Institute, Cary, NC). All patients will be blinded to their assignment.

All subjects will be seen at a preoperative visit, then again at 6, 12 and 24 months postoperatively. During each visit. a vaginal exam and a complete Pelvic Organ Prolapse Quantification (POP-Q) exam will be performed. In addition, patients will be asked to complete the Pelvic Floor Distress Inventory (PFDI-20), Incontinence Severity Index (ISI) and Pelvic Organ Prolapse/Urinary Incontinence Sexual Questionnaire (PISQ-12) questionnaires at the preoperative visit as well as the 6, 12, and 24 month postoperative visits.

Laparoscopic sacrocolpopexy will be performed using four ports: an umbilical port for the laparoscope, two ports (either 5 or 10/12 mm) in the bilateral lower quadrants, and one 5-mm port placed at the level of the umbilicus, lateral to the rectus muscle on either side for retraction. The robotic-assisted hysterectomy will be performed using the da Vinci Surgical System (Intuitive Surgical Inc., Sunnyvale, CA, USA) using five ports: a 12mm umbilical port for the laparoscopic, two 8 mm robotic ports placed 2cm inferior and 9-10cm lateral to the umbilicus bilaterally, an 8mm robotic port placed in the left axillary line at the level of the umbilicus, and a 8mm or 10/12mm accessory port either in the right upper quadrant approximately 3cm distal from the costal margin, or in the right lower quadrant, 2cm above and medial to the anterior superior iliac spine.

If a supracervical hysterectomy is to be performed, it will be done in a standard fashion. A uterine manipulator will be placed inside of the uterus. The round ligaments will be transected using cautery. The fallopian tubes and ovaries will be left in situ or removed at the time of hysterectomy depending upon the preoperative decision made between the surgeon and patient. The uterine arteries and cardinal ligaments will be cauterized laparoscopically. The uterus will be amputated at the level of the internal cervical os and the endocervical canal will be cauterized.

The sacrocolpopexy will also be performed and in a standard fashion. An end-to-end anastomosis (EEA) sizer will be placed in the vagina for manipulation of the apex as well as in the rectum for delineation of the rectovaginal septum. First, the presacral dissection will be performed with a longitudinal peritoneal incision over the sacral promontory and there is identification of the anterior longitudinal ligament. Dissection is then done caudally through the peritoneum and subperitoneal fat down to the level of the posterior cul-de-sac. The vagina is elevated cephalad using the EEA sizer and the peritoneum overlying the anterior vaginal apex is incised transversely, and the bladder is dissected off the anterior vagina using sharp dissection, creating a 4 to 5 cm pocket. If this plane is difficult to establish, the bladder will be filled in a retrograde fashion to find the correct dissection plane. Similarly, the peritoneum overlying the posterior vagina is incised, and dissection is then done overlying the vagina and extending into the posterior cul-de-sac, creating a 4 to 5 cm pocket. Once dissection is complete, the mesh graft is prepared. Subjects will have been randomized to either one of two mesh grafts:

The Y mesh is introduced into the pelvis through one of the ports. First, either then anterior or the posterior arm is fixed to the anterior or posterior vaginal wall using 6 delayed- absorbable (PDS) No. 2-0 sutures in an interrupted fashion, 1 to 2 cm apart from each other. The opposing arm of the graft is then attached to either the anterior or posterior vaginal wall, depending on which arm was placed first, in a similar fashion using 6 delayed- absorbable (PDS) No. 2-0 sutures in an interrupted fashion, 1 to 2 cm apart from each other. The stem portion of the graft is then brought to the sacral promontory and sutured to the anterior longitudinal ligament using 2 permanent (prolene) No. 0 sutures. The excess mesh is then trimmed.

The peritoneum is then closed over the exposed graft with absorbable suture. Routine cystoscopy will also be performed in order to assess for lower urinary tract injury. A vaginal exam is performed, and an anterior and/or posterior colporrhaphy and perineorrhaphy are performed if needed. Anti-incontinence procedures may also be performed if needed.

Preoperative data will include the following:

  • Patient age, race, vaginal parity, menopausal sate, BMI, prior prolapse surgery, preoperative prolapse stage
  • PFDI-20, ISI, PISQ-12
  • Preoperative hemoglobin

Data points recorded during the procedure will include:

  • Total OR time = operating room time of entry and exit
  • Total Case time = time from incision to closure
  • Concomitant procedures
  • Supracervical hysterectomy
  • Anterior colporrhaphy
  • Posterior colporrhaphy
  • Perineorrhaphy
  • Midurethral sling
  • Estimated blood loss
  • Intraoperative complications
  • EBL > 500cc
  • Vascular Injury
  • Cystotomy
  • Ureteral Injury
  • Bowel Injury - small bowel, large bowel, rectal

Postoperative data will include the following: 6, 12, 24 months

  • POP-Q exam (performed by a provider blinded to the mesh used at the time of the procedure)
  • PFDI-20, ISI, PISQ-12
  • Review of electronic medical record (inpatient notes, d/c summary, ER visits), assessing for postoperative complications
  • Reoperation for immediate complications = reoperation within 30 days of surgery
  • Abdominal Wound infection = fascial, subcutaneous, cutaneous infection requiring antibiotic treatment
  • Hematoma = intrapelvic/abdominal
  • Vaginal cuff cellulitis/Pelvic Abscess = requiring IV/PO antibiotic therapy and/or transvaginal, trangluteal or percutaneous drainage
  • DVT/PE = diagnosed with Doppler US or CT scan
  • Reoperation for SUI with pubovaginal sling (synthetic or fascial), colposuspension, injection with periurethral bulking agents
  • Reoperation for mesh exposure
  • Reoperation for recurrent POP
  • Bowel Injury/Bowel Obstruction = enterotomy, perforation, ileus, partial/complete obstruction
  • Port site or incisional hernia
  • Need for any radiologic imaging
  • Lower urinary tract injury = bladder, ureteral
  • Neurologic Injury = brachial plexus, abdominal wall (ilioinguinal, iliohypogastric), lower extremity (femoral, sciatic, common peroneal)
  • Pulmonary complications = pneumonia, pulmonary hypertension, pulmonary edema within 14 days of surgery
  • Cardiac = ACS, MI, HF within 14 days of surgery
  • Postoperative ICU admission

Protection of each subject's personal health information will be a priority in this study. One master excel file containing subject personal information including name and medical record number will be kept in a password-protected file, on a designated protected research drive on a password-protected computer in a locked office at the Cleveland Clinic. In that file, each subject will be assigned a subject identification number that will be used for the purposes of data collection in order to de-identify subjects.

All paper forms used for data collection will be kept in a research cabinet dedicated to this project which will be locked at all times, in a locked office at the Cleveland Clinic. All forms will contain de-identified information - identification numbers will correspond to the subjects listed in the master excel file.

All study data will be transferred and managed electronically using REDCap (Research Electronic Data Capture). Each subject will be entered into REDCap using the assigned identification number from the master excel file. REDCap is a secure, web-based application designed to support data capture for research studies, providing user-friendly web-based case report forms, real-time data entry validation, audit trials, and a de-identified data export mechanism to common statistical packages. They system was developed by a multi-institutional consortium which was initiated at Vanderbilt University and includes the Cleveland Clinic. The database is hosted at the Cleveland Clinic Research Datacenter in the JJN basement and is managed by the Quantitative Health Sciences Department. The system is protected by a login and Secure Sockets Layers (SSL) encryption. Data collection is customized for each study as based on a study-specific data dictionary defined by the research team with guidance from the REDCap administrator in Quantitative Health Sciences at the Cleveland Clinic.

Being tested
Vertessa® Lite Y mesh, Restorelle® Y mesh, Laparoscopic sacrocolpopexy, Robotic assisted laparoscopic sacrocolpopexy
Medical subject headings
Pelvic Organ Prolapse

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Vertessa® Lite Y meshDevice

    Via randomization, 50 surgical subjects will receive Vertessa® lite Y mesh for the treatment of vaginal vault prolapse. The patient will be blinded as to which mesh they receive.

  • Restorelle® Y meshDevice

    Via randomization, 50 surgical subjects will receive Restorelle® Y mesh for the treatment of vaginal vault prolapse.The patient will be blinded as to which mesh they receive.

  • Laparoscopic sacrocolpopexyProcedure or surgery

    The subject's surgeon will decide if their patient should have laparoscopic sacrocolpopexy upon their clinical evaluation

  • Robotic assisted laparoscopic sacrocolpopexyProcedure or surgery

    The subject's surgeon will decide if their patient should have robotic assisted laparoscopic sacrocolpopexy upon their clinical evaluation

Study groups in NCT03681223
Study groupRoleWhat they receive
Restorelle® Y meshActive comparatorAll subjects will be predetermined by their surgeon to undergo either a laparoscopic or robotic assisted laparoscopic sacrocolpopexy depending upon their clinical evaluation. The participants will then be randomized to Restorelle® sacrocolpopexy
Receives: Device: Restorelle® Y mesh; Procedure: Laparoscopic sacrocolpopexy; Procedure: Robotic assisted laparoscopic sacrocolpopexy
Vertessa® Lite Y meshExperimentalAll subjects will be predetermined by their surgeon to undergo either a laparoscopic or robotic assisted laparoscopic sacrocolpopexy depending upon their clinical evaluation. The participants will then be randomized to Vertessa® Y sacrocolpopexy
Receives: Device: Vertessa® Lite Y mesh; Procedure: Laparoscopic sacrocolpopexy; Procedure: Robotic assisted laparoscopic sacrocolpopexy

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Number of Participants With Pelvic Organ Prolapse Recurrence

    Retreatment for prolapse by either surgery or pessary

    Measured: 24 months

Secondary outcomes (5)
  1. Number of Participants With Postoperative Complications

    Any postoperative complication at 6 months, including the following:

    Wound Infection Hematoma Pelvic Abscess VTE/PE Bowel Injury, Bowel Obstruction Port Site Hernia Lower Urinary Tract Injury Neurologic Injury

    Measured: 6 months

  2. Number of Participants With Mesh Exposure

    Mesh exposure on physical exam up to 24 months following surgery

    Measured: 24 months

  3. Number of Participants With Stress Incontinence Retreatment

    Stress incontinence retreatment including urethral bulking or sling up to 24 months following surgery

    Measured: 24 months

  4. Mean Difference Between Baseline (Pre-procedure) and 24-months Post-procedure

    The PFDI-20 (Pelvic Floor Distress Inventory - 20 items) measures pelvic floor dysfunction symptoms across three scales (POPDI-6, UDI-6, CRADI-8), with each item scored 0-4; to score, sum items per scale, find the mean, then multiply by 25 (0-100 range), and add scale scores for a total PFDI-20 score (0-300), where higher scores mean worse distress. A score of 0 indicates no symptoms. Mild - less than or equal to 100; Moderate - greater than 100 but less than or equal to 200; and Severe - greater than 200.

    Measured: Baseline (pre-procedure) to 24-months (post-procedure)

  5. Mean Difference Between Baseline (Pre-procedure) and 24-months Post-procedure

    The Incontinence Severity Index (ISI) is a validated measure that quantifies urinary incontinence severity based on patient-reported frequency and amount of leakage. Scores are calculated by multiplying the frequency score (0-4) by the amount score (1-3), yielding possible total scores of 0, 1, 2, 3, 4, 6, 8, 9, and 12. The minimum possible score is 0, indicating no incontinence, and the maximum possible score is 12, indicating very severe incontinence. ISI scores are categorized as follows: 0 (dry), 1-2 (slight), 3-6 (moderate), 8-9 (severe), and 12 (very severe). Lower scores reflect less severe symptoms and represent more favorable outcomes, whereas higher scores indicate greater symptom burden and worse clinical outcomes. Improvement in incontinence severity is defined as a decrease in ISI score over time, while worsening is defined as an increase in score.

    Measured: Baseline (pre-procedure) to 24-months (post-procedure)

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted24 Sep 2018
  2. Study start18 Sep 2018
  3. Primary completion19 Dec 2023
  4. Study completion19 Dec 2023

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Model description
All subjects will be predetermined by their surgeon to undergo either a laparoscopic or robotic assisted laparoscopic sacrocolpopexy depending upon their clinical evaluation. The participants will then be randomized to either Restorelle® or Vertessa® Y sacrocolpopexy according to a computer-generated randomization.
Masking
Single blind
Who is masked
Participant
Enrolment
106 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT03681223
Sponsor's protocol ID
18-907
Acronym
Lite-Y
Status last verified
Jan 2026
First submitted
20 Sep 2018
Last updated
30 Jan 2026
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
Individual data sharing
No

Publications

  • Ganatra AM, Rozet F, Sanchez-Salas R, Barret E, Galiano M, Cathelineau X, Vallancien G. The current status of laparoscopic sacrocolpopexy: a review. Eur Urol. 2009 May;55(5):1089-103. doi: 10.1016/j.eururo.2009.01.048. Epub 2009 Feb 4.

    PubMed 19201521
  • Walters MD, Ridgeway BM. Surgical treatment of vaginal apex prolapse. Obstet Gynecol. 2013 Feb;121(2 Pt 1):354-374. doi: 10.1097/AOG.0b013e31827f415c.

    PubMed 23344287
  • Porges RF, Smilen SW. Long-term analysis of the surgical management of pelvic support defects. Am J Obstet Gynecol. 1994 Dec;171(6):1518-26; discussion 1526-8. doi: 10.1016/0002-9378(94)90395-6.

    PubMed 7802061
  • Birch C. The use of prosthetics in pelvic reconstructive surgery. Best Pract Res Clin Obstet Gynaecol. 2005 Dec;19(6):979-91. doi: 10.1016/j.bpobgyn.2005.08.013. Epub 2005 Sep 26.

    PubMed 16185932
  • Chu CC, Welch L. Characterization of morphologic and mechanical properties of surgical mesh fabrics. J Biomed Mater Res. 1985 Oct;19(8):903-16. doi: 10.1002/jbm.820190803.

    PubMed 3880350
  • Kaupp HA, Matulewicz TJ, Lattimer GL, Kremen JE, Celani VJ. Graft infection or graft reaction? Arch Surg. 1979 Dec;114(12):1419-22. doi: 10.1001/archsurg.1979.01370360073009.

    PubMed 160778
  • Salamon CG, Lewis C, Priestley J, Gurshumov E, Culligan PJ. Prospective study of an ultra-lightweight polypropylene Y mesh for robotic sacrocolpopexy. Int Urogynecol J. 2013 Aug;24(8):1371-5. doi: 10.1007/s00192-012-2021-7. Epub 2013 Jan 8.

    PubMed 23296684

Questions about this trial

What is this clinical trial studying?

A study testing Vertessa® Lite Y mesh, Restorelle® Y mesh and Laparoscopic sacrocolpopexy in people with Vaginal Vault Prolapse, run by The Cleveland Clinic at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 2 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 30 Jan 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Yes. Results are posted in the registry (first posted 30 Jan 2026). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Number of Participants With Pelvic Organ Prolapse Recurrence (time frame: 24 months). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT03681223, which also lists 7 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 30 Jan 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in